Skip to search formSkip to main contentSkip to account menu

huC242-DM1

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

cantuzumab mertansine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice
1429 Several anti-tumor antibody-maytansinoid conjugates, commonly called TAPs (tumor-activated prodrugs) are currently under… 
2003
2003
Nouvelle formulation stable
L'invention concerne une formulation stable destinee a huC242-DM1, un anticorps conjugue a un agent cytotoxique. 
2001
2001
Technology evaluation: C242-DM1, ImmunoGen Inc.
  • S. Smith
  • Current opinion in molecular therapeutics (Print)
  • 2001
  • Corpus ID: 22143103
C242-DM1 is a tumor-activated immunotoxin under development by GlaxoSmithKline plc (formerly SmithKline Beecham plc), under… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)